Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Cytosorbents (CTSO) Change in Acquisitions & Divestments (2016)

Cytosorbents filings provide 2 years of Change in Acquisitions & Divestments readings, the most recent being $249000.0 for Q3 2016.

On a quarterly basis, Change in Acquisitions & Divestments fell 83.33% to $249000.0 in Q3 2016 year-over-year; TTM through Dec 2017 was $2.2 million, a 0.0% change, with the full-year FY2016 number at $2.2 million, down 59.64% from a year prior.
Change in Acquisitions & Divestments hit $249000.0 in Q3 2016 for Cytosorbents, down from $1.9 million in the prior quarter.
In the past five years, Change in Acquisitions & Divestments ranged from a high of $1.9 million in Q2 2016 to a low of $249000.0 in Q3 2016.